Navigation Links
Nonstick coating of a protein found in semen reduces HIV infection
Date:9/23/2010

A non-stick coating for a substance found in semen dramatically lowers the rate of infection of immune cells by HIV a new study has found.

The new material is a potential ingredient for microbicides designed to reduce transmission of HIV, a team from the University of Rochester Medical Center and the University of California, San Diego reports in a forthcoming issue of the Journal of Biological Chemistry.

The coating clings to fibrous strings and mats of protein called SEVIfor semen-derived enhancer of viral infectionwhich was first discovered just three years ago. SEVI seems to attract the virus and deposit it onto the surface of T-cells, components of the immune system that are the primary target of HIV infection, and may play an important role in sexual transmission of HIV.

Like the fibrous strings that bind senile plaques associated with Alzheimer's disease, SEVI is a kind of protein superstructure called an amyloid.

Jerry Yang, associate professor of chemistry at UC San Diego and his research group developed non-stick coatings for amyloids as a potential treatment for Alzheimer's disease in 2006. Their idea was to minimize damage by preventing amyloid proteins from interacting with other molecules in the brain.

When this new amyloid, SEVI, was discovered in 2007, Yang was interested in testing whether the coating strategy might interfere with SEVI's role in promoting HIV infection.

Yang's group teamed up with a researchers led by Stephen Dewhurst, chair of the microbiology and immunology department at the University of Rochester Medical Center, who studies HIV.

"We tested one of our molecules out on SEVI and found it was able to stop SEVI-enhanced infection of HIV in cells," Yang said. "It works in semen too. Something in semen enhances viral infection SEVI and maybe other things. This molecule stops that."

When the researchers added the molecule that forms non-stick coatings to a mix of SEVI, virus and cells, rates of infection dropped to levels observed when SEVI was absent. They saw a similar effect with semen as well, evidence that this potential microbicide supplement works to inhibit infection within a mixture of proteins and other molecules found in seminal fluid.

The coating molecule is a modified form of thioflavin-T, a dye that stains amyloid proteins. It fits in between the individual small proteins that cluster to form SEVI and blocks SEVI's interactions with both the virus and the target immune cells.

"Other people have tried to do the same thing by targeting the virus or the cells it infects. What we do is target the mediator between the virus and the cells," Yang said. "By neutralizing SEVI, we prevent at least one way for HIV to attach to the cells."

The new molecule has another advantage. Unlike many current microbicide candidates aimed at reducing HIV infection, this one doesn't cause inflammation in cervical cells.

"Recent studies have shown for the first time that a topical microbicide gel can protect women from HIV-1 infection. This is a huge step forward but not a perfect solution. We need to figure out ways to further improve protection - and our studies suggest one way of doing so," said Dewhurst, who is the corresponding author of the report. "It may be possible to produce a next-generation microbicide that includes both an antiviral agent, as has been used in the past, and an agent that targets SEVI. We're very excited about exploring this idea."


'/>"/>

Contact: Susan Brown
sdbrown@ucsd.edu
858-246-0161
University of California -- San Diego
Source:Eurekalert

Related medicine news :

1. Math from the heart: Simulating stent design and coating
2. Ross Nanotechnology Corporation Introduces the NeverWet™ Coating on its First Consumer Product – The Clear-n-Clean Plunger
3. Protein clamps tight to telomeres to help prevent aging ... and support cancer
4. Protein clamps tight to telomeres to help prevent aging...and support cancer
5. Scripps Research scientists solve long-standing mystery of protein quality control mechanism
6. Function found for Alzheimers protein
7. Misfolded neural proteins linked to autism disorders
8. Will extra protein and exercise help dialysis patients? U of I profs get $2.1 million to find out
9. Researchers zero in on protein that destroys HIV
10. Munich researchers demonstrate rocking movement in the anti-stress protein Hsp90
11. Rheumatoid arthritis signaling protein reverses Alzheimers disease in mouse model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... ... ... of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum Wage’ ... 2020 and then adjusting it yearly to increase at the same rate as the median ... floor does not erode again, and make future increases more predictable. , The company is ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
Breaking Medicine Technology: